Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity

• Capital increase of €5.3 million in gross proceeds (€4.75 million cash and €0.55 million Hexagon debt roll) through the issuance of 101,923,092 new shares and warrants giving right to 127,403,865 new shares
• Obesity trial, through a combination of proceeds from the offering & existing credit lines, now fully funded to topline readout in half-year 2028
• Placement balanced between US & European institutional investors (62% & 38% respectively)
• Use of proceeds: prosecution of obesity trial in US, EU and Brazil & extension of the company’s cash runway until at least the first quarter of 2028
• All warrants from the March 2026 capital increase exercised for total proceeds of €2.8 million
• Hexagon credit line outstanding balance reduced from €1.2 million to €0.65 million through rollover into the capital increase
• 350,132,497 shares outstanding post offering and a cash /cash equivalent position of €8,9 million

Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the Company’s existing shareholders in favor of several institutional investors, for a total gross amount of €5.3 million, including €4.75 million cash and €0.55 million Hexagon debt roll (the “Placement”).